Stoneridge Investment Partners’s Opus Genetics IRD Stock Holding History

Stoneridge Investment Partners’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47K	Buy	+12,695	New	+$59.2K	0.03%	145

Other funds holding IRD

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

JIR

James Investment Research Alpha, Ohio $984M AUM 36.03% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

FCCM

First City Capital Management Savannah, Georgia $206M AUM 26.13% 1-Year Est. Return

Stoneridge Investment Partners's IRD Position: Q2 2026 in Review

Stoneridge Investment Partners opened a new position in Opus Genetics (IRD) in Q2 2026: 12,695 shares worth $47K. The stake represents 0.03% of the portfolio and ranks #145 among its holdings.

21 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

Stoneridge Investment Partners held 12,695 shares of Opus Genetics worth $47K as of Q2 2026.
Opus Genetics was a new Stoneridge Investment Partners position in Q2 2026.
Opus Genetics made up 0.03% of Stoneridge Investment Partners's portfolio in Q2 2026, its #145 holding.
21 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.